Form 4: ASMB Director Susan Mahony Receives Stock Option Grant

ASSEMBLY BIOSCIENCES, INC. Director Susan Mahony was granted 8,000 stock options with an exercise price of $24.11, aligning her interests with shareholders.

Summary

• Susan Mahony, a Director of ASSEMBLY BIOSCIENCES, INC. (ASMB), was granted 8,000 stock options.
• The stock options have an exercise price of $24.11 per share.
• The earliest transaction date for this grant was June 4, 2026.
• The options vest upon the earlier of June 4, 2027, or the date of the Issuer's 2027 annual meeting of stockholders, assuming continuous service.
• The expiration date for these stock options is June 4, 2036.
• Following this transaction, Susan Mahony beneficially owns 8,000 derivative securities directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction that slightly enhances director-shareholder alignment, without indicating significant operational or financial changes.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration date, providing a long-term incentive horizon.

Future Outlook

The vesting schedule for the granted stock options indicates an expectation of continuous service from Director Susan Mahony until at least June 2027 or the 2027 annual meeting of stockholders, aligning her incentives with the company's future performance.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like ASSEMBLY BIOSCIENCES, INC., to attract and retain experienced board members and to align their financial interests with long-term shareholder value creation. This practice is standard for public companies seeking to incentivize leadership through equity participation.

Comparison to Industry Standards

• The grant of 8,000 stock options to a non-executive director is within typical ranges for board compensation in the biotechnology sector, comparable to grants seen at similar-sized companies like smaller biotechs such as Akero Therapeutics (AKRO) or Sagimet Biosciences (SGMT) for their independent directors.
• An exercise price of $24.11, likely the market price on the grant date, is standard for at-the-money option grants to ensure future appreciation is tied to company performance.
• A 10-year option term is a common industry standard, providing ample time for value realization.

Stakeholder Impact

• Shareholders: The grant of stock options to a director generally aligns the director's financial interests with those of shareholders, potentially leading to decisions that enhance long-term shareholder value.

Next Steps

• The stock options will vest upon the earlier of June 4, 2027, or the date of the Issuer's 2027 annual meeting of stockholders, contingent on continuous service.

Key Dates

Keywords

ASMB, Assembly Biosciences, Stock Options, Insider Transaction, Director Compensation, Equity Grant, Form 4